Customize pbo-6 Antibody

Description

Anti-IL-6 Antibodies in Clinical Development

Anti-IL-6 antibodies target the IL-6 cytokine, a key mediator of inflammation in autoimmune diseases like rheumatoid arthritis (RA). Two primary strategies exist:

Direct IL-6 inhibition (e.g., olokizumab, PPV-06).
IL-6 receptor (IL-6R) blockade (e.g., tocilizumab, ziltivekimab).

Key Anti-IL-6 Antibodies from Clinical Trials

Antibody Name	Target	Clinical Phase	Key Indication	Notable Findings
Olokizumab (OKZ)	IL-6 cytokine	Phase III	Rheumatoid arthritis (RA)	- 60.9% ACR20 response vs. 40.6% placebo (p<0.01).
Ziltivekimab (ZILTI)	IL-6 ligand	Phase II	Cardiovascular risk in CKD	- Reduced hs-CRP and serum amyloid A (SAA) in hemodialysis patients.
PPV-06	IL-6 peptide	Phase I	Knee osteoarthritis (KOA)	- Induced neutralizing anti-IL-6 antibodies without autoreactive T-cell responses.

2.2. Signaling Pathways

IL-6 inhibition disrupts:

Classic signaling: Membrane-bound IL-6R activation.
Trans-signaling: Soluble IL-6R-mediated inflammation .
Trans-presentation: Dendritic cell-mediated T-cell activation (resistant to anti-IL-6 antibodies) .

3.1. Rheumatoid Arthritis (RA)

Olokizumab (OKZ):
- ACR20 response: 60.9% (64 mg q2w) vs. 40.6% placebo at 12 weeks .
- Safety: Dose-related serious adverse events (7% q2w vs. 3.2% q4w) .

3.2. Osteoarthritis (KOA)

PPV-06:
- Immunogenicity: Anti-IL-6 antibodies detected at 10 µg and 50 µg doses .
- Biomarkers: Reduced C2M and C3M levels vs. placebo .

Innovative Engineering Approaches

Recent advancements include:

Mannose 6-phosphate receptor (M6PR) engineering: Enhances cellular uptake and lysosomal degradation of antigen-antibody complexes (e.g., infliximab-AMFA) .
Bifunctional antibodies: Combine antigen binding with M6PR targeting to improve efficacy in autoimmune diseases .

Unresolved Challenges

Target specificity: Trans-presentation resistance in dendritic cells .
Long-term safety: IL-6’s role in infection defense complicates chronic use .

While "PBO-6 Antibody" remains unidentified in current literature, the robust pipeline of anti-IL-6 biologics demonstrates significant therapeutic potential, particularly in autoimmune and inflammatory diseases. Future research should clarify nomenclature discrepancies and optimize delivery mechanisms to minimize systemic toxicity.

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

pbo-6 antibody; lgc-3 antibody; F11C7.1 antibody; Proton-gated ion channel subunit pbo-6 antibody; PBoc defective protein pbo-6 antibody

Target Names

pbo-6

Uniprot No.

Q19351

Target Background

Function

This antibody forms a proton-gated ion channel with pbo-5. This channel is activated by acidification of the posterior coelomic space, which triggers posterior body wall muscle contraction (pBoc) during the defecation cycle. Notably, this antibody is not essential for the stimulation of posterior body contraction (pBoc). Furthermore, it does not bind to neurotransmitters such as acetylcholine, gamma-aminobutyric acid, glycine, serotonin, glutamate, or choline.

Database Links

KEGG: cel:CELE_F11C7.1

STRING: 6239.F11C7.1

Protein Families

Ligand-gated ion channel (TC 1.A.9) family, Acetylcholine receptor (TC 1.A.9.1) subfamily

Subcellular Location

Membrane; Multi-pass membrane protein.

Tissue Specificity

Expressed in the posterior body muscles.

Q&A

Here’s a structured FAQ collection for researchers investigating pbo-6 Antibody, synthesized from peer-reviewed studies and methodological frameworks:

What experimental designs address conflicting data in pbo-6 functional studies?

Advanced resolution strategies:

Issue	Approach	Rationale
Variability in binding affinity	Titrate antibody across concentrations (0.1–10 μg/mL) with standardized fixation protocols	Controls batch-to-batch variability
Discrepant phenotypic outcomes	Use dual CRISPR/Cas9-generated pbo-6 mutants + rescue experiments	Distinguish antibody artifacts from true gene function
Inconsistent pathway activation data	Pair antibody-based detection with orthogonal methods (e.g., RNA-seq of downstream targets)	Reduces reliance on single-method data

How to optimize pbo-6 Antibody protocols for developmental stage-specific expression analysis?

Stage-specific methodology:

Embryonic stages: Use methanol-free fixatives (e.g., 4% PFA) with 0.1% Triton X-100 permeabilization to preserve epitopes .
Adult worms: Combine antibody staining with lipophilic dyes (e.g., DiI) to correlate pbo-6 expression with neuronal aging .
Quantitative analysis: Implement automated image quantification pipelines (e.g., CellProfiler) with ≥3 biological replicates per condition .

What statistical frameworks resolve low signal-to-noise ratios in pbo-6 immunohistochemistry?

Advanced signal enhancement:

Apply background subtraction algorithms (e.g., rolling-ball radius 50 pixels) to raw images before analysis.
Use mixed-effects models to account for technical variability across slides/experimenters .
Validate findings via spatial proteomics (e.g., CODEX) in pbo-6-overexpressing transgenic lines .

How to integrate pbo-6 Antibody data with multi-omics datasets?

Integration workflow:

Map antibody-derived protein localization data to single-cell RNA-seq clusters from CeNGEN .
Perform colocalization analysis with BioGrid interaction partners using hypergeometric testing .
Validate functional associations via RNAi-phenocopy experiments: Compare antibody staining patterns in RNAi-treated vs. untreated worms .

What controls are essential when studying pbo-6 in neurodegenerative models?

Critical controls:

Biological: Age-matched pbo-6(tmXXXX) mutants (available from CGC) .
Technical:
- Pre-absorption control: Incubate antibody with excess recombinant pbo-6 antigen .
- Cross-species validation: Compare staining patterns in C. briggsae vs. C. elegans .
Experimental: Include ATPase activity assays to confirm functional impacts of observed expression changes .

How to troubleshoot pbo-6 Antibody performance in flow cytometry?

Optimization checklist:

Parameter	Recommended Setup
Fixation	0.5% formaldehyde (15 min, RT)
Permeabilization	0.05% saponin (10 min)
Antibody dilution	1:200 in PBS/1% BSA
Gating strategy	FSC-A/SSC-A → FSC-H/FSC-A → pbo-6+ vs. unstained

Validation: Compare flow cytometry results with spinning-disk confocal z-stacks .

What emerging techniques enhance pbo-6 interaction mapping?

Innovative approaches:

APEX2 proximity labeling: Fuse pbo-6 with engineered ascorbate peroxidase for spatially resolved interactome profiling .
Nanobody-based live imaging: Develop camelid single-domain antibodies for real-time pbo-6 trafficking studies .
Machine learning prediction: Train models on AlphaFold-predicted pbo-6 structures to identify cryptic epitopes .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

pbo-6 Antibody